Templates by BIGtheme NET

HC Stocks in the Rumor= ImmunoGen, Inc. (IMGN), Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Shares of ImmunoGen, Inc. (NASDAQ:IMGN) ended Tuesday session in green amid volatile trading. The shares closed up +0.07 points or 2.60% at $2.76 with 1.41 million shares getting traded. Post opening the session at $2.66, the shares hit an intraday low of $2.62 and an intraday high of $2.80 and the price vacillated in this range throughout the day. The company has a market cap of $243.74 million and the numbers of outstanding shares have been calculated to be 87.33 million shares.

ImmunoGen, Inc. (IMGN) on August 9, 2016 announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effective September 2 to pursue an opportunity closer to his primary residence in Pennsylvania.

“Charlie has made a significant contribution to ImmunoGen over these past four years,” said Mark Enyedy, President and CEO. “He played a key role in building a strong development organization, including an experienced team led by our Chief Medical Officer and Vice President, Anna Berkenblit, MD, and our Vice President, Regulatory Affairs, Theresa Wingrove, PhD. Anna and Theresa will now report directly to me, as we advance our pipeline and initiate the Phase 3 study of mirvetuximab soravtansine before the end of the year. We wish Charlie the very best in his new role.”

“ImmunoGen is successfully implementing a speed-to-market strategy for our lead product candidate, mirvetuximab soravtansine, is accelerating a strong pipeline behind it, and continues to drive significant ADC innovations,” commented Dr. Morris. “I am proud of what we have accomplished with our portfolio and look forward to ImmunoGen’s continued success, as this talented development team advances these exciting ADC programs to benefit patients with cancer.”

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) ended Tuesday session in red amid volatile trading. The shares closed down -8.52 points or -2.13% at $390.99 with 768,156.00 shares getting traded. Post opening the session at $394.34, the shares hit an intraday low of $387.00 and an intraday high of $396.17 and the price vacillated in this range throughout the day. The company has a market cap of $42.78 billion and the numbers of outstanding shares have been calculated to be 103.38 million shares.

Regeneron Pharmaceuticals Inc (REGN) on Sept. 12, 2016 announced the appointment of noted scientists Bonnie L. Bassler, Ph.D., and Huda Y. Zoghbi, M.D., to the company’s Board of Directors.

“Regeneron continues to maintain a Board of Directors primarily comprised of accomplished scientists, who provide critical input to the company’s scientific, technological and clinical strategy,” said P. Roy Vagelos, M.D., Chairman, Regeneron Board of Directors. “We are thrilled to welcome Bonnie and Huda to the Board, as both bring incredible passion and a track record of scientific achievement. Bonnie’s lifelong work as a molecular biologist and Huda’s expertise in genetics and medical research strengthen Regeneron’s scientific approach. Bonnie and Huda recognize that deep understanding of the biologic and genetic underpinnings of disease is essential to rapidly advance an innovative pipeline of potential new medicines for patients with serious diseases.”

Dr. Bassler is the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University. She has been a Howard Hughes Medical Institute Investigator since 2005. Dr. Bassler’s research focuses on bacterial cell-to-cell communication and how communication controls collective behaviors including pathogenicity. She has previously served on the Boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. Dr. Bassler also served as the President of the American Society for Microbiology. She was elected to the National Academy of Sciences in 2006, the American Academy of Arts and Sciences in 2007, and the Royal Society and the American Philosophical Society in 2012. Dr. Bassler has received many scientific honors including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine.

“I have known the Regeneron leadership team for many years, and I am proud to be joining them on the Board,” said Dr. Bassler. “Regeneron is committed to basic biology research, and I look forward to supporting its important work to unlock key questions of human disease.”

Dr. Bassler received her B.Sc. from the University of California, Davis, and her Ph.D. in Biochemistry from the Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, California, before becoming a faculty member at Princeton University.

Dr. Zoghbi is best known for her important work in neurology and the genetics of neurological diseases. She has been a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine since 1994, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital since 2010, and an investigator of the Howard Hughes Medical Institute since 1996. Dr. Zoghbi has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science. She has been awarded numerous recognitions for her work including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science.

“I have been very impressed by the caliber of scientific acumen on the Regeneron Board as well as throughout the company at every level,” said Dr. Zoghbi. “It’s an honor to join this incredible team, and, as a physician-scientist, I look forward to supporting promising research and development programs that can bring new hope to people with serious diseases.”

Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.





About James Smith

James Smith is one of the best author of health care. His articles have appeared in a number of health care sites before and now he is writing on health care for us on regular basis.

Leave a Reply

Your email address will not be published. Required fields are marked *


ăn dặm kiểu NhậtResponsive WordPress Themenhà cấp 4 nông thônthời trang trẻ emgiày cao gótshop giày nữdownload wordpress pluginsmẫu biệt thự đẹpepichouseáo sơ mi nữhouse beautiful